Investors sentiment increased to 1.69 in Q2 2019. Its up 0.40, from 1.29 in 2019Q1. It increased, as 21 investors sold Immunomedics, Inc. shares while 38 reduced holdings. 30 funds opened positions while 70 raised stakes. 155.91 million shares or 2.56% less from 160.01 million shares in 2019Q1 were reported.
Ftb, Tennessee-based fund reported 1,327 shares. Granahan Inv Management Inc Ma has 0.34% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 490,501 shares. Orbimed Advsr Lc, a New York-based fund reported 818,200 shares. 389,313 are held by Tekla Cap Mgmt Lc. State Board Of Administration Of Florida Retirement accumulated 0% or 83,334 shares. Wellington Mgmt Group Incorporated Ltd Liability Partnership has 28,415 shares for 0% of their portfolio. Gru One Trading L P reported 0% in Immunomedics, Inc. (NASDAQ:IMMU). Qs Investors has invested 0% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Guggenheim Capital Ltd Llc holds 0.02% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU) for 188,914 shares. Raymond James Associates accumulated 12,861 shares. Daiwa Securities Group stated it has 1,214 shares. Wallace Capital has invested 0.05% in Immunomedics, Inc. (NASDAQ:IMMU). Northern holds 0.01% or 1.92M shares. 732,135 were accumulated by National Bank Of America De. 851,367 are owned by Rhenman & Prtnrs Asset Mgmt Ab.
Since June 20, 2019, it had 4 insider purchases, and 0 insider sales for $33.97 million activity. 1.00M shares were bought by Avoro Capital Advisors LLC, worth $13.55 million.
The stock of Immunomedics, Inc. (NASDAQ:IMMU) is a huge mover today! The stock decreased 5.05% or $0.96 during the last trading session, reaching $18.04. About 5.64 million shares traded or 158.63% up from the average. Immunomedics, Inc. (NASDAQ:IMMU) has declined 34.91% since December 4, 2018 and is downtrending. It has underperformed by 34.91% the S&P500.
The move comes after 9 months negative chart setup for the $3.49 billion company. It was reported on Dec, 4 by Barchart.com. We have $17.50 PT which if reached, will make NASDAQ:IMMU worth $104.64M less.
Analysts await Immunomedics, Inc. (NASDAQ:IMMU) to report earnings on February, 24. They expect $-0.45 earnings per share, up 10.00 % or $0.05 from last year’s $-0.5 per share. After $-0.49 actual earnings per share reported by Immunomedics, Inc. for the previous quarter, Wall Street now forecasts -8.16 % EPS growth.
Immunomedics, Inc. (NASDAQ:IMMU) Ratings Coverage
Among 3 analysts covering Immunomedics (NASDAQ:IMMU), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Immunomedics has $30 highest and $1600 lowest target. $24.67’s average target is 36.75% above currents $18.04 stock price. Immunomedics had 5 analyst reports since June 6, 2019 according to SRatingsIntel. As per Wednesday, October 30, the company rating was maintained by Cowen & Co. Wells Fargo maintained the stock with “Market Perform” rating in Monday, September 30 report.
More notable recent Immunomedics, Inc. (NASDAQ:IMMU) news were published by: Nasdaq.com which released: “Why Twitter Shares Plunged 27% Last Month – Nasdaq” on November 11, 2019, also Nasdaq.com with their article: “Is Hewlett Packard Enterprise (HPE) a Great Value Stock Right Now? – Nasdaq” published on November 18, 2019, Nasdaq.com published: “Can These 3 Hated Chinese E-Commerce Stocks Recover? – Nasdaq” on November 15, 2019. More interesting news about Immunomedics, Inc. (NASDAQ:IMMU) were released by: Nasdaq.com and their article: “3 Stocks That Soared This Earnings Season – Nasdaq” published on November 15, 2019 as well as Nasdaq.com‘s news article titled: “Notable Friday Option Activity: IMMU, EW, IONS – Nasdaq” with publication date: November 15, 2019.
Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company has market cap of $3.49 billion. The firm engages in developing antibody-drug conjugate products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It currently has negative earnings. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.